Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEAL: Zonisamide for Sleep Abnormalities in Parkinson's Disease
jRCTs051200160Completed
- Sponsor
- Sumitomo Pharma
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial in Parkinson's disease (PD), sleep disorder and REM sleep behavior disorder (RBD) comparing Zonisamide arm with Placebo arm (2 arms). Primary endpoint: Objective Sleep Efficiency. Started Apr 2021; status: completed.
02
Drugs
zonisamide
03
Conditions
Parkinson's disease (PD)sleep disorderREM sleep behavior disorder (RBD)
Beyond the preview
Go deeper on jRCTs051200160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051200160.